No Weight Loss on Wegovy: What's Actually Going On

The biggest myth: no movement on the scales means Wegovy isn't working

This is a question our prescribers hear most weeks, and the answer almost always surprises people. Most patients who contact us convinced that Wegovy has failed them are still in the dose-escalation phase, somewhere between 0.25 mg and 1.0 mg, and expecting results that the trial evidence only shows at 1.7 mg or 2.4 mg maintenance. The STEP 1 trial (the landmark 68-week study that underpins Wegovy's UK licence) reported an average body-weight reduction of around 15% at the 2.4 mg maintenance dose, as published in the New England Journal of Medicine. That figure is a maintenance-dose figure. It was not achieved at week four.

The escalation schedule exists for good reason. Jumping straight to a high dose would, for most people, produce nausea severe enough to abandon treatment entirely. The lower steps are about your digestive system learning to tolerate the medicine, not about delivering weight loss yet. Expecting strong results before you reach the dose where the appetite effect really consolidates is the single most common reason people conclude the treatment isn't working for them.

A flat week or two during titration is not a plateau in the meaningful sense. It is the medicine doing its job quietly before the visible part begins.

What else can genuinely hold back weight loss even when the dose is right

Once someone is established on a maintenance dose and still not seeing movement, there are several physiological and behavioural factors worth examining with a prescriber. Wegovy reduces appetite, but it does not override energy intake entirely. If calorie consumption has drifted back up (sometimes unconsciously, through larger portions at the meals that remain enjoyable, or through high-calorie drinks) progress can stall even at full dose.

Sleep is a less obvious culprit. Poor or short sleep raises ghrelin (the hunger hormone) and lowers leptin, effectively working against the appetite signals Wegovy is reinforcing. Chronic stress has a similar effect via cortisol. Neither of these is a character failing; both are things worth discussing with your prescriber rather than quietly assuming the medicine is at fault.

Other medicines can also interact. Some antidepressants, antipsychotics, corticosteroids and beta-blockers are associated with weight gain or blunted weight-loss response. This does not mean stopping those medicines, but it does mean the conversation with your prescriber needs to cover everything you take. The NHS's patient information for semaglutide covers interactions in a readable format and is worth checking.

You can read more about the typical Wegovy results timeline and what the trial data shows across different stages of treatment on our Wegovy weight loss results page.

Early weeks specifically: what the first few weeks usually look like

The first weeks of Wegovy can be genuinely confusing. Some people lose a noticeable amount of weight in week one, largely fluid and digestive-tract content responding to reduced food volume and altered gastric emptying, and our guide to what happens in week one of Wegovy explains why that early shift can look so different from person to person. Others lose nothing at all until week three or four. Both patterns are within normal range. Our guide to how long Wegovy takes to work walks through the expected timeline week by week in more detail.

Water retention, hormonal fluctuations, and the timing of weigh-ins can all distort what the scales show in the short term. Weighing yourself at the same time of day, on the same surface, once a week rather than daily, gives a far more accurate picture than daily checks, which tend to amplify normal fluctuation into apparent crises.

If you are specifically in week two or week three and seeing nothing move at all, you may find our week-two stall explainer useful, and our look at why the scales often stay still in week three covers the biological reasons that window is particularly unreliable as an indicator of long-term progress.

When to raise a genuine concern with your prescriber

There is a difference between a short-term stall (normal, especially early on) and a sustained plateau at maintenance dose (worth reviewing). Under NICE guidance for semaglutide (TA875, which covers Wegovy's NHS recommendation) continuing treatment is reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose. That same clinical threshold applies in private prescribing as a sensible marker, and a good prescriber will flag it proactively rather than waiting for you to ask.

In the meantime, if your appetite has not reduced noticeably at your current dose (you feel hungry at the same times, in the same way you did before starting) tell your prescriber. This is different from losing weight slowly; it suggests the medicine's primary mechanism may not yet be working well enough at this dose, and dose titration may be appropriate sooner. See our timeline for expected results on Wegovy for a clearer picture of when to expect each stage to show up.

If you would like to talk through your progress with a clinician who can review the full picture, you can speak to our prescribers through a free consultation, a real clinician reads your case the same day, not a questionnaire algorithm.